A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
China’s answer to the Asco conference, remarkably now in its 22nd year, reminds western investors of the country’s oncology prowess.
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.